1. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E. ve Forman, D. (2011).
Global cancer statistics. CA Cancer J Clin, 61 (2), 69-90.
2. Claus, E. B., Schildkraut, J. M., Thompson, W. D. ve Risch, N. J. (1996). The genetic attributable risk of breast and ovarian cancer. Cancer, 77 (11), 2318-24.
3. Anderson, W. F., Rosenberg, P. S., Prat, A., Perou, C. M. & Sherman, M. E.
(2014). How many etiological subtypes of breast cancer: two, three, four, or more?
J Natl Cancer Inst 106.
4. Samavat, H. ve Kurzer, M. S. (2014). Estrogen metabolism and breast cancer.
Cancer Lett
5. Smith, I. E. ve Dowsett, M. (2003). Aromatase inhibitors in breast cancer. N Engl J Med, 348 (24), 2431-42.
6. Clarke, M. J. (1998). Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review. BMJ, 317 (7167), 1246-8.
7. Fang, L., Barekati, Z., Zhang, B., Liu, Z. ve Zhong, X. (2011). Targeted therapy in breast cancer: what's new? Swiss Med Wkly, 141 w13231.
8. Seal, R. L., Gordon, S. M., Lush, M. J., Wright, M. W. & Bruford, E. A.
(2011).genenames.org: the HGNC resources in 2011. Nucleic Acids Res (39), D514-9.
9. Bomar, J. M., Benke, P. J., Slattery, E. L., et al. (2003). Mutations in a novel gene encoding a CRAL-TRIO domain cause human Cayman ataxia and ataxia/dystonia in the jittery mouse. Nat Genet, 35 (3), 264-9.
10. Itoh, M., Li, S., Ohta, K., Yamada, A., Hayakawa-Yano, Y., Ueda, M., Hida, Y., Suzuki, Y., Ohta, E., Mizuno, A., Banno, Y. ve Nakagawa, T. (2011). Cayman ataxia-related protein is a presynapse-specific caspase-3 substrate. Neurochem Res, 36 (7), 1304-13.
11. Lorden, J. F., McKeon, T. W., Baker, H. J., Cox, N. & Walkley, S. U. (1984).
Characterization of the rat mutant dystonic: a new animal model of dystonia musculorum deformans. J Neurosci (4), 1925-32.
39 12. Ariel, I. M. ve Cleary, J. B. (1987). McGraw-Hill.
13. Beenken S.W.,Wanger F.B.,Bland K.I. (2004). KI Bland and Copeland III. St Loise: Saunders-Elsevier
14. Haagensen, C. D. (1986). Saunders.
15. Donegan W.L., Spratt J.S. (2002). History of Breast Cancer (5.bsk). St Louisville:
Saunders
16. Kuzey G.M. (2007). Temel Patoloji. Ankara: Güneş Kitabevi
17. Yiannakopoulou, E. (2014). Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications. Cell Oncol (Dordr), 37 (1), 1-8.
18. Apostolou, P. ve Fostira, F. (2013). Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int, (2013), 747318.
19. Mahdi, K. M., Nassiri, M. R. ve Nasiri, K. (2013). Hereditary genes and SNPs associated with breast cancer. Asian Pac J Cancer Prev, 14 (6), 3403-09.
20. Silva, F. C., Lisboa, B. C., Figueiredo, M. C., Torrezan, G. T., Santos, E. M., Krepischi, A. C., Rossi, B. M., Achatz, M. I. ve Carraro, D. M. (2014). Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. BMC Med Genet, 15 55.
21. Tonin, P., Weber, B., Offit, K., Couch, F., Rebbeck, T. R., Neuhausen, S., Godwin, A. K., Daly, M., Wagner-Costalos, J., Berman, D., Grana, G., Fox, E., Kane, M. F., Kolodner, R. D., Krainer, M., Haber, D. A., Struewing, J. P., Warner, E., Rosen, B., Lerman, C., Peshkin, B., Norton, L., Serova, O., Foulkes, W. D., Garber, J. E. ve et al. (1996). Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med, 2 (11), 1179-83.
22. Venkitaraman, A. R. (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108 (2), 171-82
23. Althuis, M. D., Fergenbaum, J. H., Garcia-Closas, M., Brinton, L. A., Madigan, M.
P. ve Sherman, M. E. (2004). Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev, 13 (10), 1558-68.
40 24. Kampert, J. B., Whittemore, A. S. ve Paffenbarger, R. S., Jr. (1988). Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk. Am J Epidemiol, 128 (5), 962-979.
25. Trichopoulos, D., MacMahon, B. ve Cole, P. (1972). Menopause and breast cancer risk. J Natl Cancer Inst, 48 (3), 605-13.
26. Ritte, R., Tikk, K., Lukanova, A., Tjonneland, A., Olsen, A., Overvad, K., Dossus, L., Fournier, A., Clavel-Chapelon, F., Grote, V., Boeing, H., Aleksandrova, K., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Palli, D., Berrino, F., Mattiello, A., Tumino, R., Sacerdote, C., Quiros, J. R., Buckland, G., Molina-Montes, E., Chirlaque, M. D., Ardanaz, E., Amiano, P., Bueno-de-Mesquita, H. B., van Gils, C.
H., Peeters, P. H., Wareham, N., Khaw, K. T., Key, T. J., Travis, R. C., Weiderpass, E., Dumeaux, V., Lund, E., Sund, M., Andersson, A., Romieu, I., Rinaldi, S., Vineis, P., Merritt, M. A., Riboli, E. ve Kaaks, R. (2013). Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study. BMC Cancer, 13 584.
27. Hartz, A. J. ve He, T. (2013). Cohort study of risk factors for breast cancer in post menopausal women. Epidemiol Health, (35), 2013003.
28. Nagata, C., Kabuto, M., Takatsuka, N. ve Shimizu, H. (1997). Associations of alcohol, height, and reproductive factors with serum hormone concentrations in postmenopausal Japanese women. Steroid hormones in Japanese postmenopausal women. Breast Cancer Res Treat, 44 (3), 235-41.
29. Bowlin, S. J., Leske, M. C., Varma, A., Nasca, P., Weinstein, A. ve Caplan, L.
(1997). Breast cancer risk and alcohol consumption: results from a large case-control study. Int J Epidemiol, 26 (5), 915-23.
30. Wu, A. H., Vigen, C., Razavi, P., Tseng, C. C. ve Stancyzk, F. Z. (2012). Alcohol and breast cancer risk among Asian-American women in Los Angeles County.
Breast Cancer Res, 14 (6), 151.
31. Reichman, M. E., Judd, J. T., Longcope, C., Schatzkin, A., Clevidence, B. A., Nair, P. P., Campbell, W. S. ve Taylor, P. R. (1993). Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women. J Natl Cancer Inst, 85 (9), 722-7.
41 32. Zheng, W., Gustafson, D. R., Sinha, R., Cerhan, J. R., Moore, D., Hong, C. P., Anderson, K. E., Kushi, L. H., Sellers, T. A. ve Folsom, A. R. (1998). Well-done meat intake and the risk of breast cancer. J Natl Cancer Inst, 90 (22), 1724-9.
33. Boyd, N. F., Martin, L. J., Noffel, M., Lockwood, G. A. ve Trichler, D. L. (1993).
A meta-analysis of studies of dietary fat and breast cancer risk. Br J Cancer, 68 (3), 627-36.
34. Link, L. B., Canchola, A. J., Bernstein, L., Clarke, C. A., Stram, D. O., Ursin, G. ve Horn-Ross, P. L. (2013). Dietary patterns and breast cancer risk in the California Teachers Study cohort. Am J Clin Nutr, 98 (6), 1524-32.
35. Sangrajrang, S., Chaiwerawattana, A., Ploysawang, P., Nooklang, K., Jamsri, P. ve Somharnwong, S. (2013). Obesity, diet and physical inactivity and risk of breast cancer in thai women. Asian Pac J Cancer Prev, 14 (11), 7023-7.
36. Engin K. (2005). Meme Kanserleri. Ankara: Nobel Tıp Kitabevi
37. Thomas, H. V., Reeves, G. K. & Key, T. J. (1997). Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control,(8), 922-8.
38. Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C. ve Mulvihill, J. J. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst, 81 (24), 1879-86.
39. Cauley, J. A., Song, J., Dowsett, S. A., Mershon, J. L. ve Cummings, S. R. (2007).
Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors. Breast Cancer Res Treat, 102 (2), 181-8.
40. Parkin, D. M., Boyd, L. & Walker, L. C. (2011). 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer, (105 Suppl 2), 77-81.
41. Parkin, D. M., Nambooze, S., Wabwire-Mangen, F. & Wabinga, H. R. (2010).
Changing cancer incidence in Kampala, Uganda, 1991-2006. Int J Cancer (126), 1187-95.
42. Aydıner, A.,Topuz, E., Aykan, Faruk. (2006). Meme Kanseri Tanı-Tedavi-Takip.İstanbul: Nobel Tıp Kitabevleri
42 43. Simpson, P. T., Gale, T., Fulford, L. G., Reis-Filho, J. S. ve Lakhani, S. R. (2003).
The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res, 5 (5), 258-62.
44. O'Malley, F. P. (2010). Lobular neoplasia: morphology, biological potential and management in core biopsies. Mod Pathol, (23 Suppl 2) 14-25.
45. Beute, B. J., Kalisher, L. ve Hutter, R. V. (1991). Lobular carcinoma in situ of the breast: clinical, pathologic, and mammographic features. AJR Am J Roentgenol, 157 (2), 257-65.
46. Beenken S.W.,Wanger F.B.,Bland K.I. (2004). KI Bland and Copeland II. St Loise:
Saunders-Elsevier
47. Roses, D.F. (2005). Breast Cancer (2.bsk). New York: Elsevier
48. Lopez-Tarruella, S. ve Martin, M. (2009). Recent advances in systemic therapy:
advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res, 11 (2), 204
49. Osborne, C. K., Yochmowitz, M. G., Knight, W. A., 3rd ve McGuire, W. L. (1980).
The value of estrogen and progesterone receptors in the treatment of breast cancer.
Cancer, 46 (12 Suppl), 2884-8.
50. Harvey, J. M., Clark, G. M., Osborne, C. K. ve Allred, D. C. (1999). Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol, 17 (5), 1474-81.
51. Osborne, C. K., Zhao, H. ve Fuqua, S. A. (2000). Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol, 18 (17), 3172-86.
52. Leyland-Jones, B. (2002). Trastuzumab: hopes and realities. Lancet Oncol, 3 (3), 137-44.
53. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J. ve Press, M. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 20 (3), 719-26.
43 54. Tevaarwerk, A. J. ve Kolesar, J. M. (2009). Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther, (31 Pt 2), 2332-48.
55. Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M. ve Sliwkowski, M. X. (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell, 5 (4), 317-28.
56. De, P. ve Leyland-Jones, B. (2010). Whither HER2-related therapeutics? J Clin Oncol, 28 (7), 1091-96.
57. Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., Fumoleau, P. ve Gianni, L. (2010).
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol, 28 (7), 1138-44.
58. Johnson, W.G., Murphy, M., Murphy, W.I., Bloom, A.D. (1978). Recessive Congenital cerebellar disorder in a genetic isolate: CPD type VII?. Neurology, (28),352-3
59. Brown, L., Mueller, M., Benke, P.J. (1984). A non progressive cerebellar ataxia n Grand Cayman Island. Neurology, (34), 273.
60. Nystuen, A., Benke, P. J., Merren, J., Stone, E. M. ve Sheffield, V. C. (1996). A cerebellar ataxia locus identified by DNA pooling to search for linkage disequilibrium in an isolated population from the Cayman Islands. Hum Mol Genet, 5 (4), 525-31.
61. Boyd, J. M., Malstrom, S., Subramanian, T., Venkatesh, L. K., Schaeper, U., Elangovan, B., D'Sa-Eipper, C. ve Chinnadurai, G. (1994). Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins. Cell, 79 (2), 341-51.
62. Buschdorf, J. P., Li Chew, L., Zhang, B., Cao, Q., Liang, F. Y., Liou, Y. C., Zhou, Y. T. ve Low, B. C. (2006). Brain-specific BNIP-2-homology protein Caytaxin relocalises glutaminase to neurite terminals and reduces glutamate levels. J Cell Sci, 119 (Pt 16), 3337-50.
44 63. Zhou, Y. T., Guy, G. R. ve Low, B. C. (2005). BNIP-2 induces cell elongation and membrane protrusions by interacting with Cdc42 via a unique Cdc42-binding motif within its BNIP-2 and Cdc42GAP homology domain. Exp Cell Res, 303 (2), 263-74.
64. Panagabko, C., Morley, S., Hernandez, M., Cassolato, P., Gordon, H., Parsons, R., Manor, D. ve Atkinson, J. (2003). Ligand specificity in the CRAL-TRIO protein family. Biochemistry, 42 (21), 6467-74.
65. Gupta, A. B., Wee, L. E., Zhou, Y. T., Hortsch, M. ve Low, B. C. (2012). Cross-species analyses identify the BNIP-2 and Cdc42GAP homology (BCH) domain as a distinct functional subclass of the CRAL_TRIO/Sec14 superfamily. PLoS One, 7 (3), 33863.
66. Grelle, G., Kostka, S., Otto, A., Kersten, B., Genser, K. F., Muller, E. C., Walter, S., Boddrich, A., Stelzl, U., Hanig, C., Volkmer-Engert, R., Landgraf, C., Alberti, S., Hohfeld, J., Strodicke, M. ve Wanker, E. E. (2006). Identification of VCP/p97, carboxyl terminus of Hsp70-interacting protein (CHIP), and amphiphysin II interaction partners using membrane-based human proteome arrays. Mol Cell Proteomics, 5 (2), 234-44.
67. Cabral Miranda, F., Adao-Novaes, J., Hauswirth, W. W., Linden, R., Petrs-Silva, H. & Chiarini, L. B. (2014). CHIP, a carboxy terminus HSP-70 interacting protein, prevents cell death induced by endoplasmic reticulum stress in the central nervous system. Front Cell Neurosci (8), 438.
68. Dickey, C. A., Patterson, C., Dickson, D. & Petrucelli, L. (2007). Brain CHIP:
removing the culprits in neurodegenerative disease. Trends Mol Med,(13), 32-8.
69. Kajiro, M., Hirota, R., Nakajima, Y., Kawanowa, K., So-ma, K., Ito, I., Yamaguchi, Y., Ohie, S. H., Kobayashi, Y., Seino, Y., Kawano, M., Kawabe, Y., Takei, H., Hayashi, S., Kurosumi, M., Murayama, A., Kimura, K. & Yanagisawa, J. (2009).
The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways.
Nat Cell Biol,(11), 312-9
70. Takano, T., Lin, J. H., Arcuino, G., Gao, Q., Yang, J. & Nedergaard, M. (2001).
Glutamate release promotes growth of malignant gliomas. Nat Med, (7), 1010-5.
71. Shin, S. S., Martino, J. J. & Chen, S. (2008). Metabotropic glutamate receptors (mGlus) and cellular transformation. Neuropharmacology, (55), 396-402.
45 72. Buschdorf, J. P., Chew, L. L., Soh, U. J., Liou, Y. C. ve Low, B. C. (2008). Nerve growth factor stimulates interaction of Cayman ataxia protein BNIP-H/Caytaxin with peptidyl-prolyl isomerase Pin1 in differentiating neurons. PLoS One, 3 (7), 2686.
73. Driver, J. A., Zhou, X. Z. ve Lu, K. P. (2014). Regulation of protein conformation by Pin1 offers novel disease mechanisms and therapeutic approaches in Alzheimer's disease. Discov Med, 17 (92), 93-99.
74. Liou, Y. C., Zhou, X. Z. ve Lu, K. P. (2011). Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci, 36 (10), 501-514.
75. Aoyama, T., Hata, S., Nakao, T., Tanigawa, Y., Oka, C. ve Kawaichi, M. (2009).
Cayman ataxia protein caytaxin is transported by kinesin along neurites through binding to kinesin light chains. J Cell Sci, 122 (Pt 22), 4177-85.
76. Schubbert, S., Shannon, K. & Bollag, G. (2007). Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer,(7), 295-308.
77. Pan, C. Q. & Low, B. C. (2012). Functional plasticity of the BNIP-2 and Cdc42GAP Homology (BCH) domain in cell signaling and cell dynamics. FEBS Lett,(586), 2674-91.
78. Tekedereli, I., Alpay, S. N., Akar, U., Yuca, E., Ayugo-Rodriguez, C., Han, H. D., Sood, A. K., Lopez-Berestein, G. & Ozpolat, B. (2013). Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Mol Ther Nucleic Acids,(2), 121.
79. Shao, L., Tekedereli, I., Wang, J., Yuca, E., Tsang, S., Sood, A., Lopez-Berestein, G., Ozpolat, B. & Ittmann, M. (2012). Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res,(18), 6648-57.
80. Redmile-Gordon, M. A., Armenise, E., White, R. P., Hirsch, P. R. & Goulding, K.
W. (2013). A comparison of two colorimetric assays, based upon Lowry and Bradford techniques, to estimate total protein in soil extracts. Soil Biol Biochem, (67), 166-173.
46 81. Borahay, M. A., Lu, F., Ozpolat, B., Tekedereli, I., Gurates, B., Karipcin, S. &
Kilic, G. S. (2013). Mullerian inhibiting substance suppresses proliferation and induces apoptosis and autophagy in endometriosis cells in vitro. ISRN Obstet Gynecol,(2013), 361489.
82. Sikora, K. M., Nosavanh, L. M., Kantheti, P., Burmeister, M. & Hortsch, M.
(2012). Expression of Caytaxin protein in Cayman Ataxia mouse models correlates with phenotype severity. PLoS One, (7), 50570.
83. Charafe-Jauffret, E., Ginestier, C., Monville, F., Finetti, P., Adelaide, J., Cervera, N., Fekairi, S., Xerri, L., Jacquemier, J., Birnbaum, D. & Bertucci, F. (2006). Gene expression profiling of breast cell lines identifies potential new basal markers.
Oncogene,(25), 2273-84.
84. Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J. P., Tong, F., Speed, T., Spellman, P. T., DeVries, S., Lapuk, A., Wang, N. J., Kuo, W. L., Stilwell, J. L., Pinkel, D., Albertson, D. G., Waldman, F. M., McCormick, F., Dickson, R. B., Johnson, M. D., Lippman, M., Ethier, S., Gazdar, A. & Gray, J. W. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell,(10), 515-27.
85. Soltysik, K. & Czekaj, P. (2013). Membrane estrogen receptors - is it an alternative way of estrogen action? J Physiol Pharmacol,(64), 129-42.
86. Thomas, P., Pang, Y., Filardo, E. J. & Dong, J. (2005). Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells.
Endocrinology, (146), 624-32.
87. Khongkow, M., Olmos, Y., Gong, C., Gomes, A. R., Monteiro, L. J., Yague, E., Cavaco, T. B., Khongkow, P., Man, E. P., Laohasinnarong, S., Koo, C. Y., Harada-Shoji, N., Tsang, J. W., Coombes, R. C., Schwer, B., Khoo, U. S. & Lam, E. W.
(2013). SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis,(34), 1476-86.
88. Mauro, L., Pellegrino, M., Giordano, F., Ricchio, E., Rizza, P., De Amicis, F., Catalano, S., Bonofiglio, D., Panno, M. L. & Ando, S. (2015). Estrogen receptor-alpha drives adiponectin effects on cyclin D1 expression in breast cancer cells.
FASEB J.
47 89. Schiffmann, S., Sandner, J., Birod, K., Wobst, I., Angioni, C., Ruckhaberle, E., Kaufmann, M., Ackermann, H., Lotsch, J., Schmidt, H., Geisslinger, G. & Grosch, S. (2009). Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis,(30), 745-52.
90. Bateman, N. W., Sun, M., Hood, B. L., Flint, M. S. & Conrads, T. P. (2010).
Defining central themes in breast cancer biology by differential proteomics:
conserved regulation of cell spreading and focal adhesion kinase. J Proteome Res, (9), 5311-24.
91. In, S. J., Kim, S. H., Go, R. E., Hwang, K. A. & Choi, K. C. (2015).
Benzophenone-1 and Nonylphenol Stimulated MCF-7 Breast Cancer Growth by Regulating Cell Cycle and Metastasis-Related Genes Via an Estrogen Receptor alpha-Dependent Pathway. J Toxicol Environ Health A,(78), 492-505.
92. D'Amelio, M., Cavallucci, V. & Cecconi, F. (2010). Neuronal caspase-3 signaling:
not only cell death. Cell Death Differ,(17), 1104-14
93. Woo, M., Hakem, R., Furlonger, C., Hakem, A., Duncan, G. S., Sasaki, T., Bouchard, D., Lu, L., Wu, G. E., Paige, C. J. & Mak, T. W. (2003). Caspase-3 regulates cell cycle in B cells: a consequence of substrate specificity. Nat Immunol,(4), 1016-22.
94. Bassnett, S. & Mataic, D. (1997). Chromatin degradation in differentiating fiber cells of the eye lens. J Cell Biol,(137), 37-49.
95. Fernando, P., Kelly, J. F., Balazsi, K., Slack, R. S. & Megeney, L. A. (2002).
Caspase 3 activity is required for skeletal muscle differentiation. Proc Natl Acad Sci U S A, (99), 11025-30.
96. Fujita, J., Crane, A. M., Souza, M. K., Dejosez, M., Kyba, M., Flavell, R. A., Thomson, J. A. & Zwaka, T. P. (2008). Caspase activity mediates the differentiation of embryonic stem cells. Cell Stem Cell, (2), 595-601.
97. Levkau, B., Koyama, H., Raines, E. W., Clurman, B. E., Herren, B., Orth, K., Roberts, J. M. & Ross, R. (1998). Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell,(1), 553-63.
48 98. Blessing, N. A., Brockman, A. L. & Chadee, D. N. (2014). The E3 ligase CHIP mediates ubiquitination and degradation of mixed-lineage kinase 3. Mol Cell Biol,(34), 3132-43
49